Shots:

• The collaboration will utilize Philochem’s DNA-encoded chemical library technology platform to identify small molecule compounds with ultra-high affinity for tumor-associated antigens that bind to specific targets
• Janssen will exercise its options to use these identified ligands as therapies for drug discovery and development activities
• Philogen’s focuses are to discover and develop targeted anti-cancer therapeutics which selectively assessable at the site of disease to help spare normal tissue

Click here to­ read full press release

Ref: Globe Newswire | Image: Janssen